Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Combination therapies with azacitidine for MDS

Mikkael Sekeres • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Antibodies Azacitidine Checkpoint inhibitors Lenalidomide Vorinostat

Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses azacitidine monotherapy versus a combination with lenalidomide or vorinostat to treat myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Mikkael Sekeres

1:20
Outcomes for Hispanic patients with ALL treated at centers across the US
Mikkael Sekeres • 11 Dec 2021
2:06
Updates from the NHLBI-MDS Natural History study
Mikkael Sekeres • 11 Dec 2021
1:58
Updates from the PANTHER trial
Mikkael Sekeres • 11 Dec 2021
1:34
Exciting news at the ASH 2021 plenary scientific session
Mikkael Sekeres • 6 Dec 2021

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals